Evidence map›Paper›PMID 34896022›Full record

ArticleClinical genitourinary cancer2022

Safety and Efficacy of Reproductive Organ-Sparing Radical Cystectomy in Women With Variant Histology and Advanced Stage.

Sunil H Patel, Shirley Wang, Meredith R Metcalf, Natasha Gupta, Andrew Gabrielson, Esther Lee, Mary Rostom, Phil Pierorazio, Armine Smith, Noah Hahn and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical genitourinary cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Sunil H PatelThe Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, MD. Electronic address: Spate167@jhmi.edu.
Shirley WangThe Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, MD.
Meredith R MetcalfDepartment of Urology, New York University, New York, NY.
Natasha GuptaThe Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, MD.
Andrew GabrielsonThe Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, MD.
Esther LeeThe Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, MD.
Mary RostomThe Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, MD.
Phil PierorazioDivision of Urology, University of Pennsylvania, Philadelphia, PA.
Armine SmithThe Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, MD.
Noah HahnThe Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, MD; Department of Urology, New York University, New York, NY.
Mark SchoenbergDepartment of Urology, Montefiore Medical Center, Einstein School of Medicine, Bronx, NY.
Max KatesThe Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, MD.
Jean Hoffman-CensitsThe Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, MD; Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, MD.
Trinity J BivalacquaDivision of Urology, University of Pennsylvania, Philadelphia, PA.
Johns Hopkins University · USUniversity of Pennsylvania · USAlbert Einstein College of Medicine · USNew York University · US

Funding

NYU Training Program in Healthcare Delivery Science and Population Health ResearchT32HS026120 · AHRQ · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HORWITZ, LEORA, SCHWARTZ, MARK D · 2018 to 2023
$3.4M
AHRQ HHS T32 HS026120
6 · The paper itself

Abstract

purposeMuscle invasive bladder cancer surgical management has been historically a radical cystoprostatectomy in males and an anterior exenteration in females. Uterine, ovarian, and vaginal preservation are utilized, but raise concerns regarding risk to oncologic control, especially in variant histopathology or advanced stage. MATERIALS AND

methodsA retrospective single institutional analysis identified radical cystectomies performed in women, including those with variant histology, which were defined as reproductive organ sparing (uterine, vaginal, and ovary sparing) or nonorgan sparing. The Kaplan-Meier method was used for recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) in patients with advanced disease.

resultsFrom 2000 to 2020, 289 women were identified, 188 underwent reproductive organ-sparing cystectomy. No statistical differences were noted for clinical parameters or presence of variant histology for organ-sparing (ROS) and nonorgan-sparing (non-ROS). Positive margin rates did not differ for ROS and non-ROS; 4.3% vs. 7.9%, P = .19, respectively. Median RFS was not statistically significantly different for ROS vs. non-ROS (26.1 vs. 15.3 months) P = .937 hazard ratio (HR) 1.024. CSS was not statistically different for ROS vs. non-ROS (36.3 vs. 28.6 months), P = .755 HR 0.9. OS was not statistically different for ROS vs. non-ROS (25.8 vs. 23.8 months), P = .5 HR = 1.178. Variant histology did not change survival (HR 1.1, P = .643).

conclusionIn this analysis, ROS in women with advanced disease did not increase positive margin rates or decrease RFS, CSS, or OS compared to non-ROS. Variant histology did not decrease survival odds. Based on preoperative assessment and intraoperative findings, ROS in patients with variant histology and advanced disease should be considered.

Indexed as

CystectomyUrinary Bladder NeoplasmsFemaleGenitaliaHumansMaleMargins of ExcisionNeoplasm Recurrence, LocalReactive Oxygen SpeciesRetrospective StudiesTreatment OutcomeReactive Oxygen SpeciesBladder Cancer, Female cystectomy, Reproductive organ sparing, Variant Histology, advanced disease

Identifiers

PMID34896022
PMCPMC12410766
OpenAlexW3212232831

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.